Access to Medicines Foundation (2014) The Access to Medicine Index 2014, Haarlem: Access to Medicines Foundation, www.accesstomedicinesindex.org/.Google Scholar

Alkoby, Asher (2012, “Improving Access to Essential Medicines: International Law and Normative Change,” in Forman, Lisa and Kohler, Jillian Clare, eds., Access to Medicines as a Human Right: Implications for Pharmaceutical Industry Responsibility, Toronto, Buffalo, and London: University of Toronto Press, pp. 46–74.CrossRefGoogle Scholar

Babar, Zaheer Ud Din, Ibrahim, Mohamed Izham Mohamed, Singh, Harpal, Burkal, Nadeem Irfan, et al. (2007) “Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia,” PLoS Medicine 4 (3): e82. doi:10:1371/journal.pmed.0040082.CrossRefGoogle ScholarPubMed

Bajaj, Vikas (2012) “India Weighs Providing Free Drugs at State-Run Hospitals,” The New York Times, July 6, Business Day, pp. 1–2.Google Scholar

Beall, Reed and Kuhn, Randall (2012) “Trends in Compulsory Licensing of Pharmaceuticals since the Doha Declaration: A Database Analysis,” PLoS Medicine 9 (1): e1001154.CrossRefGoogle ScholarPubMed

Bigdeli, Maryam, Peters, David H., and Wagner, Anita K. (2014) Medicines in Health Systems: Advancing Access, Affordability and Appropriate Use, Geneva: Alliance for health Policy and Systems Research and the World Health Organization.Google Scholar

Bill and Melinda Gates Foundation (2015), www.gatesfoundation.org/Google Scholar

Binagwaho, Agnès, Freeman, Richard, Scott, Kirstin, Badrichani, Anne, et al. (2015) “Improving International Accountability – a Tool for Protecting Health as a Basic Human Right,” Health and Human Rights Journal, published online 4/15, www.hhrjournal.org/...impoving-internaGoogle Scholar

Cameron, A., Ewen, M., Ross-Degnan, D., Ball, P., et al. (2009) “Medicine Prices, Availability, and Affordability in 36 Developing and Middle-income Countries: A Secondary Analysis,” The Lancet 373 (9659): 240–249.CrossRefGoogle ScholarPubMed

CESCR (Committee on Economic, Social and Cultural Rights) (2000) General Comment 14: The Right to the Highest Attainable Standard of Health, U.N. Doc. E.C.12.2000.4.EN.Google Scholar

Commission on Intellectual Property Rights (2002) Integrating Intellectual Property Rights and Development Policy: Report of the Commission on Intellectual Property Rights, London.Google Scholar

Congressional Budget Office (2007) Research on the Comparative Effectiveness of Medical Treatments: Issues and Options for an Expanded Federal Role, Washington, DC: U.S. Government, www.cbo.gov/sites/default/files/12-18-comparativeeffectiveness.pdf.Google Scholar

Correa, Carlos M. (2009) “Intellectual Property Rights and Inequalities in Health Outcomes,” in Labonté, Ronald, Schrecker, Ted, Packer, Corrine, and Runnels, Vivien, eds., Globalization and Health: Pathways, Evidence and Policy, New York and Abington, UK: Routledge, pp. 263–288.Google Scholar

Correa, Carlos M. and Matthews, Duncan (2011) The Doha Declaration Ten Years on Its Impact on Access to Medicines and the Right to Health, Discussion Paper, United Nations Development Programme, www.undp.org/...Discussion_P...Google Scholar

Drahos, Peter (2008) “‘Trust Me’: Patent Offices in Developing Countries,” American Journal of Law & Medicine 34: 151–174.CrossRefGoogle ScholarPubMed

Drugs for Neglected Diseases initiative website (2015) www.dndi.org/.Google Scholar

Dutfield, Graham (2008) “Delivering Drugs to the Poor: Will the TRIPS Amendment Help?” American Journal of Law & Medicine 34: 07–124.CrossRefGoogle Scholar

Editorial (2013) “What Price Affordable Access?” Nature Biotechnology 31 (6): 467.CrossRefGoogle Scholar

Forman, Lisa (2008) “‘Rights’ and Wrongs: What Utility for the Right to Health in Reforming Trade Rules on Medicines?” Health and Human Rights 10: 37–48.CrossRefGoogle ScholarPubMed

Forman, Lisa and Kohler, Jillian Clare (2012) “Introduction: Access to Medicines as a Human Right – What Does It Mean for Pharmaceutical Industry Responsibilities,” in Forman, Lisa and Kohler, Jillian Clare, eds., Access to Medicines as a Human Right: Implications for Pharmaceutical Industry Responsibility, Toronto, Buffalo, and London: University of Toronto Press, pp. 3–24.CrossRefGoogle Scholar

Gagne, Joshua J. and Choudhry, Niteesh K. (2011) “How Many ‘Me Too’ Drugs Is Too Many?” JAMA 305 (7): 711–712.CrossRefGoogle ScholarPubMed

Gagnon, Marc-André (2013) “Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health,” Journal of Law, Medicine & Ethics 41: 571–580.CrossRefGoogle ScholarPubMed

GAVI the Vaccine Alliance Website 92015) www.gavi.org/.Google Scholar

Global Health Watch (2006) Global Health Watch 2005–2006: An Alternative World Health Report, London: Zed Publishing Company for the People’s Health Movement, Medact, Medico International, Third World Network, Health Action International, and Asociación Latinoamericana de Medicina Social.Google Scholar

Global Health Watch (2009) Global Health Watch 2: An Alternative World Report, London: Zed Publishing Company for the People’s Health Movement, Medact, and the Global Equity Gauge.Google Scholar

Global Health Watch (2014) Global Health Watch 4: An Alternative World Health Report, London and New York: Zed Publishing Company for the People’s Health Movement, Medact, and the Global Equity Gauge Alliance.Google Scholar

Gootendorst, Paul, Hollis, Aidan, Levine, David K., Pogge, Thomas, et al. (2011) “New Approaches to Rewarding Pharmaceutical Innovation,” Canadian Medical Association Journal 183 (6): 681–685.CrossRefGoogle Scholar

Grabowski, Henry G., DiMasi, Joseph A., and Long, Genia (2015) “The Roles of Patents and Research and Development Incentives in Biopharmaceutical Innovation,” Health Affairs 34 (2): 302–310.CrossRefGoogle ScholarPubMed

Grover, Anand (2009) Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, Human Rights Council, A/HRC/11/12.Google Scholar

Grover, Anand (2011) Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, Expert Consultation on Access to Medicines as a Fundamental Component of the Right to Health, Human Rights Council, A/HRC/17/43.Google Scholar

Helfer, Laurence R. and Austin, Graeme W. (2011) Human Rights and Intellectual Property: Mapping the Global Interface, New York and Melbourne: Cambridge University Press.CrossRefGoogle Scholar

Heywood, Mark (2009) “South Africa’s Treatment Action Campaign: Combining Law and Social Mobilization to Realize the Right to Health,” Journal of Human Rights Practice 1 (1): 14–16, doi: 10.1093.CrossRefGoogle Scholar

Hoen, Ellen’t, Berger, Jonathan, Calmy, Alexandra, and Suerie, Moon (2011) “Driving a Decade of Change: HIV/AIDS, Patents and Access to Medicines for All,” Journal of the International AIDS Society 14:15, www.jiasociety.org/content/14/1/15.CrossRefGoogle ScholarPubMed

Hogerzeil, Hans V. (2004) “The Concept of Essential Medicines: Lessons for Rich Countries,” British Medical Journal 329: 1169–1172.CrossRefGoogle ScholarPubMed

Hogerzeil, Hans V. (2006) “Essential Medicines and Human Rights: What Can They Learn from Each Other,” Bulletin of the World Health Organization 84 (5): 371–375.CrossRefGoogle ScholarPubMed

Hogerzeil, Hans V., Liberman, Jonathan, Wirtz, Veronika, Kishore, Sandeep P., et al. (2013) “Promotion of Access to Essential Medicine for Non-communicable Diseases: Practical Implications of the UN Political Declaration,” The Lancet 281: 680–689.CrossRefGoogle Scholar

Human Rights Council (2013) Access to Medicines in the Context of the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, Twenty-third session, agenda item 3, A/HRC/23/L.10/Rev.1.Google Scholar

Hunt, Paul (2008) Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, UN Doc. A/63/263.Google Scholar

Hunt, Paul and Khosla, Rajat (2008) “The Human Right to Medicines,” Sur 5 (8): 99–116.Google Scholar

Hunt, Paul and Khosla, Rajat (2010) “Are Drug Companies Living Up to Their Human Rights Responsibilities? The Perspective of the Former United Nations Special Rapporteur (2002–2008),” PLoS Medicine 7 (9): e1000330.CrossRefGoogle ScholarPubMed

Illingworth, Patricia (2012) “Corporate Social Responsibility and the Right to Essential Medicines,” Forman, Lisa and Kohler, Jillian Clare, eds., Access to Medicines as a Human Right: Implications for Pharmaceutical Industry Responsibility, Toronto, Buffalo, and London: University of Toronto Press, pp. 75–88.CrossRefGoogle Scholar

International Convention on the Elimination of All Forms of Racial Discrimination (1969) United Nations General Assembly Resolution 2106 (XX) of December 21, 1965, Annex 20 U.N. GAOR Supp (No 14) at 47, U.N. Doc. A/6014, entered into force on January 4, 1969.Google Scholar

Jorgensen, Paul D. (2013) “Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda,” The Journal of Law, Medicine & Ethics 4 (3): 561–570.CrossRefGoogle Scholar

Khosla, Rajat and Hunt, Paul (2012) “Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines,” in Forman, Lisa and Kohler, Jillian Clare, eds., Access to Medicines as a Human Right: Implications for Pharmaceutical Industry Responsibility, Toronto, Buffalo, and London: University of Toronto Press, pp. 25–45.CrossRefGoogle Scholar

Koivusalo, Meri and Mackintosh, Maureen (2009) “Global Public Action in Health and Pharmaceutical Policies: Politics and Policy Priorities,” Innovation Knowledge Development Working Paper No. 45, The Open University.Google Scholar

Kulkarni, Kaustubh and Mohanty, Suchitra (2013) “Novartis Loses Landmark India Cancer Drug Patent Case,” Reuters Business and Financial News, www.reuters.com.assets/print?aid=USBRE93002120130401.Google Scholar

Light, Donald W., Lexchin, Joel, and Darrow, Jonathan J. (2013) “Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs,” The Journal of Law, Medicine & Ethics 41: 590–600.CrossRefGoogle ScholarPubMed

Light, Donald W. and Warburton, Rebecca (2011) “Demythologizing the High Costs of Pharmaceutical Research,” BioSocieties, The London School of Economics and Political Science 1745–8552: 1–17.CrossRefGoogle Scholar

Malpani, Rohit and Kamal-Yanni, Mohga (2006) Patents versus Patients: Five Years after the Doha Declaration, Oxfam International, Oxfam Briefing Paper 95.Google Scholar

MDG Gap Task Force Report (2008) Delivering on the Global Partnership for Achieving the MDGs, New York: United Nations Publications.Google Scholar

MDG Gap Task Force Report (2009) Strengthening the Global Partnership for Development in a Time of Crisis, New York: United Nations Publications.Google Scholar

MDG Gap Task Force Report (2012) The Global Partnership for Development: Making Rhetoric a Reality, New York: United Nations Publications.Google Scholar

MDG Gap Force Report (2013) The Challenges We Face, New York: United Nations Publications.Google Scholar

Médecin Sans Frontières (MSF) (2015) Website: The Access Campaign, www.msfacess.org/TheAccessCampaign.Google Scholar

Media Centre (2014) Hepatitis C, fact sheet no. 164, Geneva: World Health Organization.Google Scholar

Media Centre (2015) “WHO Moves to Improve Access to Lifesaving Medicines for Hepatitis C, Drug-resistant TB and Cancers,” Geneva: World Health Organization, www.who.int/mediacentre/news/releases/2015/new-essential-medicines-list/en/.Google Scholar

Mossialos, Elias, Wenzl, Martin, Osborn, Robin, and Anderson, Chloe, eds. (2015) International Profiles of Health Systems, 2014, New York: Commonwealth Fund.Google Scholar

Nagarajan, Rmea (2015) “Free Drugs Plan Gets a Quiet Burial,” Times of India, http://timesof india.com/india/free-drugs-plam-gets-a-quiet-burial/articleshow/4680931.com.Google Scholar

National Institute of Allergy and Infectious Disease Website (2015) www.niad.nih...Google Scholar

Oke, Emmanuel Kolawole (2013) “Incorporating a Right to Health Perspective into the Resolution of Patent Law Disputes,” Health and Human Rights 15 (2): 97–107.Google ScholarPubMed

Ollove, Michael (2014) “Could New Hepatitis C Drugs Bust State Budgets?” USA Today, March 3, www.usatoday.com/story/news/nation/2014/03/03/stateline-hepat...Google Scholar

Perrone, Matthew (2014) “Soaring Drug Prices Draw Senate Scrutiny,” Associated Press, November 20, www.sanders.semate.gpv/newsroom/must-read/soaring-generic-d...Google Scholar

PLoS Medicine Editors (2010) “Drug Companies Should Be Held More Accountable for Their Human Rights Responsibilities,” PLoS Medicine 7 (9): E1000344.Google Scholar

Reidenberg, Marcus M. and Walley, Tom (2004) “Commentary: The Pros and Cons of Essential Medicines for Rich Countries,” British Medical Journal 329: 1172.CrossRefGoogle ScholarPubMed

Ritter, Geralyn (2010) “Are Drug Companies Living Up to Their Human Rights Responsibilities: The Merck Perspective,” PLoS Medicine 7 (9): el000343.CrossRefGoogle ScholarPubMed

Rodwin, Marc A. (2013) “Introduction: Institutional Corruption and the Pharmaceutical Industry,” The Journal of Law, Medicine & Ethics 41: 544–552.CrossRefGoogle Scholar

Ruggeri, Kai and Nolte, Ellen (2013) Pharmaceutical Pricing: The Use of External Reference Pricing, Rand Europe, www.rand.org.Google Scholar

Servick, Kelly (2015) “The Drug Push,” Science 348 (6237): 850–853.CrossRefGoogle ScholarPubMed

Shah, Anup (2014) “Foreign Aid for Development Assistance,” Global Issues, www.globalissues.org.Google Scholar

Silverman, Ed (2014) “Will Gilead’s Hepatitis C Drug Bust State Budgets?” WSJ Pharmalot, July 17, http://blogs.wsj.com/pharmalot/2014/07/17/will-gileads-hepatitis-c-dr...Google Scholar

Statista, (2015) The Statistics Portal, www.statista.com/topics/1764/global-pharmaceutical-industry/Google Scholar

The Editorial Board (2015) “Runaway Drug Prices,” The New York Times, May 5, A22.Google Scholar

The Global Fund website (2015) www.theglobalfund.org...Google Scholar

United Nations Development Group (2003) Indicators for Monitoring the Millennium Development Goals, New York: United Nations.Google Scholar

United Nations Human Rights Council (2013) Access to Medicines in the Context of the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, A/HRC/23/L.10/ Rev.1.Google Scholar

UNITAID (2014) The Trans-Pacific Partnership Agreement: Implications for Access to Medicines and Public Health, Geneva: UNITAID Secretariat, www.unitaid.eu.Google Scholar

UNITAID website (2015) www.unitaid.eu/who/about-unitaid.Google Scholar

WHO/UNICEF (1978) Primary Health Care: Report of the International Conference on Primary Health Care, Alma-Ata, USSR, September 6–12. Health for all, series 1: Geneva: World Health Organization.Google Scholar

World Health Organization (n.d.) Access to Affordable Essential Medicines. www.who.int/medicines/.../MDG08ChapterE...Google Scholar

World Health Organization (2003) The Selection and Use of Essential Medicines,” Report of the WHO Expert Committee 2002.Google Scholar

World Health Organization (2004) What Are Essential Medicines? www.who.int/topic/essential_medicines/en/l.Google Scholar

World Health Organization (2008) WHO Medicines Strategy 2008–2013, working draft. www.who.int/medicines/publications/medicines_strategy.Google Scholar

World Health Organization, Health Action International (2003) Medicine Prices – a New Approach to Measurement, Geneva: World Health Organization, http://whqlibdoc.who.int/hq/2003/WHOEDMPAR2003.2.pdf.Google Scholar

World Trade Organization (1994) Agreement on Trade-Related Aspects of Intellectual Property Rights, 1869 U.N.T.S. 299.Google Scholar

World Trade Organization (2001) Ministerial Conference Fourth Session, Doha, November 9–14, Declaration on the TRIPS Agreement and Public Health, T/MIN(01)/DEC/2.Google Scholar

World Trade Organization (2013) “Responding to Least Developed Countries’ Special Needs in ip,” www.wto.org/english/tratop-?e/trips._e/ldc/e.htm.Google Scholar